Maternal RSV vaccination for infant protection: A systematic review and meta‐analysis of phase 3 trials with an integrated economic evaluation
International Journal of Gynecology & Obstetrics · 2026-04 · 173 (1) · 63-73
DOI: 10.1002/ijgo.70641 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift International Journal of Gynecology & Obstetrics, online erschienen am 04.11.2025. Verfasst von Johnatan Torres-Torres und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Reproductive and Perinatal Health Research, Instituto Nacional de Perinatología Isidro Espinosa de los Reyes, Mexico City, Mexico. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus Vaccines, Vaccination, Pregnancy Complications, Infectious. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Respiratory syncytial virus (RSV) is a leading cause of hospitalization and mortality in early infancy. Maternal immunization offers a preventive strategy, but uncertainties regarding safety and economic value have limited its implementation.
Objectives
To synthesize phase 3 randomized trial evidence on the efficacy and safety of maternal RSV vaccination and to estimate its potential population and economic impact. By integrating a scenario‐based modeling framework derived from pooled meta‐analytic estimates, this review provides high‐certainty, policy‐relevant evidence to guide maternal immunization strategies in diverse settings. Search Strategy PubMed, MEDLINE, Scopus, and Google Scholar were searched up to April 2025 using predefined terms for RSV vaccination, pregnancy, and randomized controlled trials (RCTs). Selection Criteria Phase 3 RCTs comparing maternal RSV vaccination with placebo and reporting neonatal or maternal outcomes were included. Non‐randomized studies, monoclonal antibody trials, or reports lacking extractable data were excluded. Data Collection and Analysis Two reviewers independently screened studies, extracted data, and assessed risk of bias (RoB‐2). Pooled risk ratios (RR) and absolute risk differences were calculated with random‐effects models. Certainty of evidence was graded using Grading of Recommendations Assessment, Development and Evaluation (GRADE). A scenario‐based cost‐effectiveness model was applied to the Mexican birth cohort. Main Results Four phase 3 RCTs (17 391 women) were included. Maternal RSV vaccination halved the risk of infant RSV infection (risk ratio [RR] 0.47, 95% confidence interval [CI]: 0.29–0.76; number needed to vaccinate [NNV] 85) and reduced severe disease by 64% (RR 0.36, 95% CI: 0.21–0.60; NNV 127). No increased risks were observed for preterm birth, pre‐eclampsia, or stillbirth. Certainty was moderate (any RSV) to high (severe RSV). In Mexico, universal vaccination at list price (US$295 per dose) would prevent approximately 20 769 infections and 228 neonatal deaths annually, though with high costs per case averted. At public‐sector pricing (US$50 per dose), cost‐effectiveness improved substantially.
Conclusions
Maternal RSV vaccination is effective, safe, and potentially cost‐justifiable in high‐burden settings, supporting its integration into national immunization programs. PROSPERO registration: CRD420251014636 (March 2025).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Reproductive and Perinatal Health Research, Instituto Nacional de Perinatología Isidro Espinosa de los Reyes, Mexico City, Mexico.
- Obstetric and Gynecology Department, Hospital General de México "Dr Eduardo Liceaga", Mexico City, Mexico.
- Iberoamerican Research Network in Obstetrics, Gynecology and Translational Medicine, Mexico City, Mexico.
- Maternal-Fetal Department, Instituto Materno Infantil del Estado de Mexico, Toluca, Mexico.
- Laboratory of Immunogenomics and Metabolic Diseases, Instituto Nacional de Medicina Genomica, Mexico City, Mexico.
ORCID-Profile: Johnatan Torres-Torres, Lourdes Rojas-Zepeda, José Rafael Villafan-Bernal, Raigam Martinez-Portilla, Salvador Espino-Y-Sosa, Elsa Romelia Moreno-Verduzco, Irma Eloisa Monroy-Muñoz, Ameyran Yolanda Gonzalez-Guerrero, Juan Mario Solis-Paredes, Javier Perez Duran
Zitieren
APA
Torres-Torres, J., Rojas-Zepeda, L., Villafan-Bernal, J. R., Martinez-Portilla, R., Espino-Y-Sosa, S., Cerda-Flores, P., Moreno-Verduzco, E. R., Monroy-Muñoz, I. E., Gonzalez-Guerrero, A. Y., Solis-Paredes, J. M., & Duran, J. P. (2026). Maternal RSV vaccination for infant protection: A systematic review and meta‐analysis of phase 3 trials with an integrated economic evaluation. International Journal of Gynecology & Obstetrics, 173(1), 63-73. https://doi.org/10.1002/ijgo.70641
Vancouver
Torres-Torres J, Rojas-Zepeda L, Villafan-Bernal JR, Martinez-Portilla R, Espino-Y-Sosa S, Cerda-Flores P, et al. Maternal RSV vaccination for infant protection: A systematic review and meta‐analysis of phase 3 trials with an integrated economic evaluation. International Journal of Gynecology & Obstetrics. 2026;173(1):63-73. doi:10.1002/ijgo.70641
BibTeX
@article{TorresTorres2026,
author = {Torres-Torres, Johnatan and Rojas-Zepeda, Lourdes and Villafan-Bernal, José Rafael and Martinez-Portilla, Raigam and Espino-Y-Sosa, Salvador and Cerda-Flores, Pablo and Moreno-Verduzco, Elsa Romelia and Monroy-Muñoz, Irma Eloisa and Gonzalez-Guerrero, Ameyran Yolanda and Solis-Paredes, Juan Mario and Duran, Javier Perez},
title = {Maternal RSV vaccination for infant protection: A systematic review and meta‐analysis of phase 3 trials with an integrated economic evaluation},
journal = {International Journal of Gynecology & Obstetrics},
year = {2026},
volume = {173},
number = {1},
pages = {63--73},
doi = {10.1002/ijgo.70641}
}
EUVIMED